Athersys

Athersys, Inc. engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Athersys, Inc. is a biotechnology company, which focuses on the field of regenerative medicine. It engages in the discovery and development of therapies designed to extend and enhance the quality of human life. The firm offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas. The company was founded by John J. Harrington and Gil van Bokkelen on October 24, 1995 and is headquartered in Cleveland, OH.

Athersys, Inc. (NASDAQ:ATHX ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants Cindy Jacobs - President, Chief Medical Officer & Director Jerry Wan - Principal Accounting Officer Daniel Camardo - Chief Executive Officer Conference Call Participants Michael Higgins - Ladenburg Thalmann François Brisebois - Oppenheimer John Vandermosten - Zacks Vernon Bernardino - H.C. Wainwright Jim Molloy - Alliance Global Partners Operator Good day, ladies and gentlemen, and welcome to the Athersys Second Quarter 2022 Earnings Conference Call.

Athersys, Inc. (ATHX) CEO Daniel Camardo on Q2 2022 Results - Earnings Call Transcript

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys, Inc. (NASDAQ: ATHX) announced today its financial results for the three and six months ended June 30, 2022 and provided a business update. Second quarter 2022 Corporate and Operational Highlights: Corporate Restructuring Implemented a restructuring of our organization with the intention of significantly reducing expenses, conserving cash, improving focus of the Company's activities and becoming more attractive to potential financial and strategic partners.

Athersys Reports Second Quarter 2022 Financial Results and Provides Business Update

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARS--Athersys, Inc. (Nasdaq: ATHX) announces today results of a radiation countermeasure study conducted by the Armed Forces Radiobiology Research Institute (AFRRI), a Department of Defense research laboratory under the leadership of the Uniformed Services University of the Health Sciences, that showed intravenous MultiStem® (invimestrocel) administration provided benefit in an animal model of acute radiation syndrome (ARS). The results demonstrate that the administration

Athersys Announces Favorable Preclinical Results for MultiStem® Treatment in Defense Department Radiation Countermeasure Study and Upcoming Webinar to Review Preclinical Research With MultiStem Across Multiple Indications

CLEVELAND--(BUSINESS WIRE)---- $ATHX #ARDS--Athersys Appoints Kasey Rosado as Interim Chief Financial Officer - Brings Operational Excellence and Financial Experience to Leadership Team

Athersys Appoints Kasey Rosado as Interim Chief Financial Officer

Comera Life Sciences Holdings Inc

Chimerix

InflaRx

Revelation Biosciences

Biotech penny stocks to watch this week. The post Best Penny Stocks To Buy As Recession Begins?

Best Penny Stocks To Buy As Recession Begins? 5 Biotech Stocks To Watch

CLEVELAND--(BUSINESS WIRE)---- $ATHX #MultiStem--Athersys, Inc. (Nasdaq: ATHX) will release its second quarter 2022 financial results at approximately 4:00 PM Eastern Time on Thursday, August 11, 2022, and will host a conference call shortly thereafter at 4:30 PM Eastern Time to review the results. Members of the management team will host the call as follows: Date August 11, 2022 Time 4:30 p.m. (Eastern Time) Live webcast registration Webcast link Phone registration Call registration link We encourage shareholders

Athersys to Host Second Quarter Financial Results Call

CLEVELAND--(BUSINESS WIRE)---- $ATHX--Athersys, Inc. (Nasdaq: ATHX) today announced that its equity purchase agreement with Aspire Capital Fund LLC (Aspire Capital) has been terminated. The Company continues to evaluate alternative financing options to support continuing operations. After several discussions with Aspire Capital, Athersys received notice on July 6, 2022 of termination of the equity purchase agreement, effective immediately. The equity purchase agreement had been in place since May 12, 202

Athersys and Aspire Capital Fund Terminate Relationship

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX--In connection with the Company's cost-cutting and restructuring initiatives, the Board of Directors approved reducing its size from 10 to 5 members.

Athersys Announces Board of Directors Slate for 2022 Annual Meeting of Stockholders and Director Departures

CLEVELAND--(BUSINESS WIRE)---- $ATHX--The Athersys Annual Meeting of Stockholders is rescheduled to Thursday, July 28, 2022, 8:30 a.m. ET

Athersys Postpones Annual Meeting of Stockholders

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys will moderate a KOL panel of neurology experts to share their perspectives on the topline data from the TREASURE study.

Athersys Hosting KOL Panel Event to Discuss TREASURE Data

LiveOne

Sesen Bio Inc.

Stocks Under $1 To Watch This Week. The post Top Penny Stocks To Buy For Under $1?

Top Penny Stocks To Buy For Under $1? 3 To Watch This Week

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys announces a corporate restructuring plan to reduce costs and prioritize its lead clinical programs for MultiStem cell therapy.

Athersys Announces Restructuring and Management Changes to Focus on Its Existing Clinical Programs

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

Athersys Inc's (NASDAQ: ATHX) partner, Healios K.K. has reported topline results for its Japan ischemic stroke study, TREASURE.

Athersys-Partnered Japanese Ischemic Stroke Study Disappoints, Shares Plunge

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #Athersys--Topline data from the largest cell therapy clinical trial ever run in Japan, evaluating Athersys' MultiStem (invimestrocel) for ischemic stroke.

Athersys Announces That Its Partner, HEALIOS K.K., Reported Topline Data From the TREASURE Multistem Ischemic Stroke Study

Vinco Ventures

Chicken Soup for the Soul Entertainment

Mullen Automotive

Redbox Entertainment

Short squeeze penny stocks to watch right now. The post Penny Stocks To Buy Now?

Penny Stocks To Buy Now? Top Short Squeeze Stocks To Watch

CLEVELAND--(BUSINESS WIRE)--Athersys, Inc. (Nasdaq: ATHX), announced today that Dan Camardo, Chief Executive Officer, will participate virtually in the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami, Florida. The Company's management team will also participate in one-on-one meetings with institutional investors during the conference. Investors interested in arranging a meeting with the Company's management during the conference should contact meetings@hcwo.com

Athersys to Participate in the H.C. Wainwright Global Investment Conference

Amicus Therapeutics

Lexicon Pharmaceuticals

Moderna

Nanobiotix SA

United Therapeutics

Verrica Pharmaceuticals Inc

The beaten-down state of biotech stocks is a major pulling point for investors who are aiming for market-leading returns. The post 7 Biotech Stocks With Key Catalysts for May appeared first on InvestorPlace.

7 Biotech Stocks With Key Catalysts for May

Gran Tierra Energy

IAMGOLD

Check these three penny stocks out for your watchlist The post Are These Hot Penny Stocks on Your Watchlist Right Now? appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Are These Hot Penny Stocks on Your Watchlist Right Now?

CLEVELAND--(BUSINESS WIRE)---- $ATHX #MultiStem--Athersys will host a conference call after its partner Healios announces the topline data for its TREASURE study evaluating MultiStem for stroke.

Athersys Reports First Quarter 2022 Results

Company has been focused on developing a viable treatment for stroke for nearly 20 years. Article will discuss chances for success in treating stroke with Phase 3 results to be reported in Japan this month.

Athersys: Focus On Stroke

CLEVELAND--(BUSINESS WIRE)---- $ATHX #investorconference--Athersys executives will present in person and participate in one-on-one meetings with institutional investors.

Athersys to Participate in the Bank of America Securities 2022 Global Healthcare Conference

CLEVELAND, Ohio--(BUSINESS WIRE)---- $ATHX #earningsdate--Athersys Q1 Conference Call to be Held Following Announcement of Phase 2/3 TREASURE Data in May.

Athersys to Announce First Quarter Financial Results on May 6

Aterian

Creative Medical Technology Holdings

Clever Leaves Holdings Inc

CYREN

Enservco

ION Geophysical

Alaunos Therapeutics

Short squeeze penny stocks to watch. The post Penny Stocks To Buy?

Penny Stocks To Buy? 8 Short Squeeze Stocks To Watch Now

On 04/11/2022, Athersys shares spiked after a long downward slide, soon they were back on the skids. Athersys' big dollar late-stage therapeutic candidates are highly attractive.

Athersys - Hero Or Zero Opportunity

News for Athersys Stock (ATHX)